Subjects -> PATENTS, TRADEMARKS AND COPYRIGHTS (Total: 26 journals)
Showing 1 - 9 of 9 Journals sorted alphabetically
Berkeley Technology Law Journal     Free   (Followers: 14)
Expert Opinion on Therapeutic Patents     Hybrid Journal   (Followers: 12)
Fordham Intellectual Property, Media and Entertainment Law Journal     Open Access   (Followers: 20)
IIC - International Review of Intellectual Property and Competition Law     Hybrid Journal   (Followers: 28)
International Data Privacy Law     Hybrid Journal   (Followers: 22)
International Journal of Intellectual Property Management     Hybrid Journal   (Followers: 30)
IP Theory     Open Access   (Followers: 12)
JIPITEC Journal of Intellectual Property, Information Technology and E-Commerce Law     Open Access   (Followers: 24)
John Marshall Journal of Information Technology & Privacy Law     Full-text available via subscription   (Followers: 7)
John Marshall Review of Intellectual Property Law     Free   (Followers: 10)
Journal of Copyright in Education & Librarianship     Open Access   (Followers: 33)
Journal of Data Protection & Privacy     Full-text available via subscription   (Followers: 6)
Journal of Intellectual Property Law & Practice     Hybrid Journal   (Followers: 30)
Journal of Intellectual Property Rights (JIPR)     Open Access   (Followers: 23)
Law, State and Telecommunications Review     Open Access   (Followers: 1)
Marquette Intellectual Property Law Review     Open Access   (Followers: 14)
Northwestern Journal of Technology and Intellectual Property     Open Access   (Followers: 8)
Propiedad Intelectual     Open Access   (Followers: 1)
Recent Patents on Anti-Cancer Drug Discovery     Hybrid Journal   (Followers: 2)
Recent Patents on Anti-Infective Drug Discovery     Hybrid Journal   (Followers: 1)
Reports of Patent, Design and Trade Mark Cases     Hybrid Journal   (Followers: 5)
Revista La Propiedad Inmaterial     Open Access  
The Journal of World Intellectual Property     Hybrid Journal   (Followers: 26)
Ticaret ve Fikri Mülkiyet Hukuku Dergisi     Open Access  
Web Journal of Current Legal Issues     Open Access   (Followers: 6)
World Patent Information     Hybrid Journal   (Followers: 17)
Similar Journals
Journal Cover
Recent Patents on Anti-Infective Drug Discovery
Journal Prestige (SJR): 0.376
Citation Impact (citeScore): 1
Number of Followers: 1  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 1574-891X - ISSN (Online) 2212-4071
Published by Bentham Science Homepage  [128 journals]
  • Meet Our Editorial Board Member
    • PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Editorial: Nanomedicines for the Treatment of Tuberculosis: Role of
           Nanocarriers and Functional Excipients
    • PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Nanoemulsion for the Effective Treatment and Management of Anti-tubercular
           Drug Therapy
    • Abstract: Background: Tuberculosis is considered as one of the deadliest diseases of human existence. Since ancient age the treatment of tuberculosis has been highly challenging primarily owing to the pathogenic nature of the Mycobacterium and its diverse spots of localization in human body including lungs, liver, spleen, eye, meninges and lymph nodes. Methods: The conventional drug therapy employed for the treatment of tuberculosis is not highly satisfactorily owing to low oral bioavailability of the drugs. The evolution of nano-technology recently in few decades has completely revolutionized the treatment of diverse diseases and so is the tuberculosis. Nanotechnology not only possesses enormous potential for improving the biopharmaceutical performance, but also allows the delivery of therapeutic molecules to the desired site of action. Diverse types of nanocarriers have been employed for the treatment of tuberculosis infections. In this regard, nanoemulsions are considered as one of the promising alternatives for augmenting the bioavailability of the antitubercular drugs through oral route for improving their therapeutic efficacy. Conclusion: The nanoemulsion loaded with antitubercular drugs can easily cross the biological barriers to reach the systemic circulation and consequently in the target for reducing the load of Mycobacterium tuberculosis. Besides, the lipidic nature of such systems facilitates targeting of the drugs to the lymph nodes, thus improves drug bioavailability and reduction of the dosing frequency. In lieu of this, the present article compiles the basics of nanoemulsions in brief along with an updated account on their applications in delivering antitubercular drugs for enhanced immunization. Moreover, overview of patent literature published in this area has also been included in the manuscript.
      PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Nano-carriers for the Treatment of Tuberculosis
    • Abstract: Background: Nano size based drug delivery systems are an emerging technique with the potential to develop new strategies involving handling of drugs at the nanometer scale. There are many nano-based drug delivery systems that have been extensively reported as drug carriers for the treatment of tuberculosis. Methods: There are numerous nano sized drug delivery systems like lipid nanoparticles, polymeric micelle, carbon nanotubes and polymeric nanoparticles that have been reported for a long time to treat diseases. There are a number of drawbacks in conventional TB dosage forms such as the development of multiple drug resistance, resulting in intolerable toxicity and high drug dose required. So, to overcome the drawbacks of conventional therapy, there is a need for a new drug delivery system with an aim to reduce the side effects of drug treatment. Nano-sized based drug delivery systems have considerable potential for the treatment of tuberculosis. These delivery systems have several advantages like high stability, high loading capacity, the feasibility of incorporation of both hydrophilic and hydrophobic drugs, and feasibility of variable routes of administration, and prolonged drug release from the matrix. These advantages enable enhanced drug solubility, bioavailability, reduced dosing frequency, high targeting, and may resolve the problem of non adherence to prescribed therapy, which is one of the major obstacles in the control of tuberculosis epidemics. Conclusion: This article gives an exhaustive review of patents and research papers published over the years on the challenges, the current treatment therapy of the disease faces, and potential advantages of nano sized formulations to offer more effective treatment and prevention for tuberculosis.
      PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Nanoemulsion-Based Transdermal Drug Delivery System for the Treatment of
           Tuberculosis
    • Abstract: Background: The nanoemulsion based carriers are the most suitable delivery systems for poorly soluble drugs to improve the drugs solubility, permeation of drugs and ultimately increase bioavailability by transdermal therapeutic system. The nanoemulsion for poorly soluble drugs is admirable and offered several advantages over others drug delivery. Methods: For nanoemulsions formulation, they have to deliver the energetic element at the specific organ with nominal uneasiness. Because of the prevention of hepatic first pass uptake transdermal course excel usual crest and trough plasma shape that usually comfort the administration. The antitubercular drugs relate to the formulation of Poly DL-Lactide-Co-Glycolide nanoparticles having an active substance encapsulated within and that the encapsulated substances are stable with respect to each other. Conclusion: The present study aimed to explore the challenges and methods in order to increase the solubility of poorly aqueous soluble drug for improved bioavailability alongwith relative study of toxicity problems related to anti-tubercular drug.
      PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Current Approaches and Future Prospects of Nanomedicine in Tuberculosis
           Therapy
    • Abstract: Background: Tuberculosis (TB), which is caused by the Mycobacterium tuberculosis, is a serious threat and one of the major health problems worldwide. Objective: In recent years, an estimated of 9.6 million TB cases occurred and 1.5 million death occurred due to TB worldwide. Conclusion: The present review is an attempt to introduce this disease focusing on the pathophysiology of the disease, the current approaches and the related patents for treatment and the future planning for combating this disease.
      PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches
           & Challenges
    • Abstract: Background: The diseases tuberculosis, triggered by intracellular pathogens, is a major problem for the global medical professionals. Treatments for these diseases through conventional dosage form consist of long-term therapy with multiple drugs, leading to several side effects and contribute to low patient compliance and drug resistance. The pathogens are found to be situated in the intracellular compartments of the cells, which ultimately results in additional blockades to effective treatment. Therefore, improved and more efficient therapies for such intracellular diseases are required. Methods: This review discusses the potential of nanomedicine and related patents to improve intracellular disease chemotherapy. To complete the objective, we searched bibliographic databases of indexed literature using a focused and structured criteria. The quality and characteristics of selected papers were assessed using standard parameters with qualitative analysis having a conceptual framework. Results: Nanoparticle-based drug delivery systems are suitable for the treatment of illnesses, such as tuberculosis. Due to the unique size-dependent properties, nanocarriers such as nanoparticles, liposomes, niosomes and microspheres offer the opportunity to develop new therapeutic and diagnostic tools. The ability to integrate drugs into nanosystems displays a new standard in pharmacotherapy that could be used for cell-targeted drug therapy. Experimental data showed the possibility of intermittent chemotherapy with main antituberculosis drugs by employing nanocarriers. Besides the advantage of the controlled release of medications in organs, the other benefits of the nanocarriers include the possibility of various routes of therapy, reduction in drug dosage and adverse effects, reduced possibility of drug interactions, and drug-resistant targeting. Published literature including patented studies suggests that nanomedicine mediated drug delivery may improve tuberculosis chemotherapy by offering benefits such as targeting to the specific organs, sustained and controlled drug release, tuberculosis diagnosis, drug delivery to the pathogen’s intracellular location, and tuberculosis vaccine development. Conclusion: The properties of nanomedicine may prove beneficial in developing improved, efficacious or alternative therapies for tuberculosis diseases.
      PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Recent Complications and Issues in Tuberculosis Treatment
    • Abstract: Background: Tuberculosis is one of the major communicable diseases which can be prevented and cured. The prevalence of tuberculosis infection is more despite this disease causes major morbidity and mortality. To establish connection between tuberculosis (TB) related stigma and hindrance in search of a treatment after the inception of symptoms associated with tuberculosis. Methods: Physicians conducted the interviews using a structured questionnaire. Information from the medical reports available at health care centers (especial results of sputum microscopy, radiological and other investigations) was also distracted. Patients is said to be infected with TB having a minimum two initial +ve sputum smears or one +ve sputum smear and chest radiographic abnormalities along with active pulmonary TB as determined by clinician; one sputum +ve culture specimen +ve for Mycobacterium tuberculosis. High resolution computed tomography (HRCT), a new susceptible technique shows erratically disseminated military nodules. The organs associated and extents of lesions of miliary TB in the pulmonary tuberculosis are examined by ultrasonography, computed tomography (CT) and magnetic resonance imaging (MRI). Histopathological examination of tissue biopsy is a conservative and fast technique for the separation of mycobacterium tuberculosis and assessment of choroid tubercles in fundus. Conclusion: Even though numerous prognostic markers have been described which envisage mortality, yet untreated miliary TB has a serious outcome within one year. A high index of clinical research, early diagnosis and timely institution of anti-tuberculosis treatment can be life-saving. Response to first-line anti-tuberculosis drugs is good. Anti–tuberculosis drugs are patent.
      PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • New Drugs and Vaccines for Tuberculosis
    • Abstract: Background: Tuberculosis (TB) is an infectious disease that resulted in estimated 9.6 million new cases in 2014 and 1.5 million deaths. The available drug regimen for TB is time consuming which more often leads to the patient non compliance which then results in occurrence of drug resistant TB (Multi-drug and extremely drug resistant TB) in several portions of the world. Methods: The dangerous combinations of TB and HIV is taking its toll on human health. The foremost factor is non- profit associated with the development of anti TB drugs. There is almost 10 different drugs in various levels of trials whereas the vaccine development is focusing more on adult vaccine rather than a child vaccine. Results: More than 15 vaccine candidate are in various stages of pipelines. Present compilation gives an account for various drug candidates and vaccine products in various stages of drug development. Also included is a recent collection of patents for assay methods, potential drug candidates/classes and vaccination products. Conclusion: The need is for improvement in the activity and chemical and biological description of under development compounds. Lastly the set up for clinical and appropriate uses for running a reliable clinical trial is a necessary prerequisite.
      PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Macrophage Targeted Cellular Carriers for Effective Delivery of
           Anti-Tubercular Drugs
    • Abstract: Background: Newly developed vaccine VPM1002 confers paradigm swing in the prophylactic treatment of tuberculosis (TB). Multi-drug resistant and latent TB in adults as well as in underprivileged patients is instigating menace over world population if the host is immune-compromised. Methods: One third of the world’s population is infected with TB. Recently it is estimated around 9.6 million people around the world became sick with TB disease. There were 1.5 million TB-related deaths worldwide. Therefore with the advent in biotechnology and Nano engineering, newly adapted survival molecular mechanism of Mycobacterium tuberculosis, new targets receptors on alveolar macrophages must be explored out for eradication of TB from the globe. Macrophage acts as a reservoir of phagocytic receptors to execute diverse physiological functions as well as to perform defense mechanism. Results: Advances in novel carriers open new era for the treatment of tuberculosis which remains a very substantial global health encumbrance. Different binding receptors especially mannose, folate and scavenger receptors are attractive platform for internalization of therapeutics in alveolar macrophage. Nano-carriers and nano-devices designed after the acquaintance of receptor composition and functioning affords site specific targeting of biodegradable and biocompatible drug delivery systems for the treatment of tuberculosis offering complete cure and patient compliance. Conclusion: This chapter encompasses recent studies on nanocarriers and new treatment strategies for tuberculosis. In spite of the budding benefits of nano carriers, many limitations still remain to be overcome such as poor oral stability, instability in circulation, inadequate tissue distribution as well as toxicity to normal cells.
      PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Patent Selections
    • PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
  • Acknowledgements to Reviewers
    • PubDate: Tue, 05 Jun 2018 04:22:49 -070
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 34.204.191.145
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-